Mitoxantrone hydrochloride (NSC-310739) in lymphoma - A Southwest Oncology Group study

Charles A. Coltman, Terri M. McDaniel, Stanley P. Balcerzak, Francis S. Morrison, Daniel D. Von Hoff

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.

Original languageEnglish (US)
Pages (from-to)65-70
Number of pages6
JournalInvestigational New Drugs
Issue number1
StatePublished - Mar 1983
Externally publishedYes


  • Hodgkin's disease
  • mitoxantrone
  • non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Mitoxantrone hydrochloride (NSC-310739) in lymphoma - A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this